132 related articles for article (PubMed ID: 35114803)
1. Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer.
McAllister J; Amin S; Lin C
Future Oncol; 2022 Mar; 18(10):1273-1284. PubMed ID: 35114803
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
3. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
4. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
[TBL] [Abstract][Full Text] [Related]
5. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
6. The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2021 Apr; 21(1):387. PubMed ID: 33836694
[TBL] [Abstract][Full Text] [Related]
7. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
8. Impact of facility type on survival after pancreatoduodenectomy for small pancreatic adenocarcinoma (≤ 2 cm).
Maegawa FB; Ashouri Y; Bartz-Kurycki M; Ahmad M; De La Rosa E; Philipovskiy A; Riall TS; Konstantinidis IT
Am J Surg; 2021 Jul; 222(1):145-152. PubMed ID: 33131577
[TBL] [Abstract][Full Text] [Related]
9. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
[TBL] [Abstract][Full Text] [Related]
10. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
11. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
12. Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma.
Chu QD; Zhou M; Peddi P; Medeiros KL; Zibari GB; Shokouh-Amiri H; Wu XC
HPB (Oxford); 2017 Dec; 19(12):1046-1057. PubMed ID: 28967535
[TBL] [Abstract][Full Text] [Related]
13. A Tale of Two Cancers: Traveling to Treat Pancreatic and Thyroid Cancer.
White MG; Applewhite MK; Kaplan EL; Angelos P; Huo D; Grogan RH
J Am Coll Surg; 2017 Jul; 225(1):125-136.e6. PubMed ID: 28473189
[TBL] [Abstract][Full Text] [Related]
14. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
16. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
17. Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma.
Deng Y; Tu H; Pierzynski JA; Miller ED; Gu X; Huang M; Chang DW; Ye Y; Hildebrandt MAT; Klein AP; Zhao R; Lippman SM; Wu X
Eur J Cancer; 2018 Mar; 92():20-32. PubMed ID: 29413686
[TBL] [Abstract][Full Text] [Related]
18. Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer.
Mirkin KA; Hollenbeak CS; Wong J
J Gastrointest Surg; 2018 Aug; 22(8):1365-1375. PubMed ID: 29520648
[TBL] [Abstract][Full Text] [Related]
19. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
